Molecular imaging is among the most promising areas of development in biotechnology.

Cardinal UW and Health collaborate to advance use of molecular imaging in medical investigations and trials Cardinal Health and the University of Washington today announced a forward thinking public-private collaboration made to advance the usage of molecular imaging in medical investigations and trials. Molecular imaging is among the most promising areas of development in biotechnology, where specific radiopharmaceuticals, or Positron Emission Tomography imaging agents, are injected into the body to detect and trace irregular cellular functions that are connected with health problems such as for example heart disease, neurological disorders and several forms of cancers http://www.silagra-rx.com/what-is-sildenafil.html .

silagra-rx.com

Cardium resolves continued listing deficiencies with NYSE Amex Cardium Therapeutics today reported that it all had received notice from NYSE Regulation that the Company is now considered to have got regained compliance with the listing requirements of the NYSE Amex LLC . Related StoriesExpanded use for IntelliCap with further CE Mark for aspiration of fluidsLiposomal sizing and the Coulter basic principle: an interview with Professor Melvin E. KlegermanIn the communication from its listing exchange, Cardium was informed that based upon a review of information supplied by the Company and publicly available info, including the Company’s Form 8-K filed on January 3, 2012, the business has resolved the continued listing deficiencies referenced in the NYSE Amex LLC’s letter dated November 26, 2010, as previously reported.